A Phase I Multicenter, Dose-Escalation Study of IDEC-152 (Anti-CD23 Monoclonal Antibody) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia.

Trial Profile

A Phase I Multicenter, Dose-Escalation Study of IDEC-152 (Anti-CD23 Monoclonal Antibody) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia.

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Jun 2015

At a glance

  • Drugs Lumiliximab (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Sponsors Biogen
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 04 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Jun 2009 Planned end date (Dec 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top